Ampelopsin induces apoptosis by regulating multiple c-Myc/S-phase kinase-associated protein 2/F-box and WD repeat-containing protein 7/histone deacetylase 2 pathways in human lung adenocarcinoma cells

XIN-MEI CHEN1, XIAN-BIAO XIE2*, QING ZHAO1, FANG WANG3, YANG BAI4, JUN-QIANG YIN2, HONG JIANG3, XIAO-LIN XIE3, QIANG JIA3 and GANG HUANG2

1Department of Biochemistry, School of Basic Science, Guangzhou Medical University, Guangzhou, Guangdong 510182; 2Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510080; 3Institute of Biology, Guizhou Academy of Sciences, Guiyang, Guizhou 550009; 4Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong 510230, P.R. China

Received November 19, 2013; Accepted September 12, 2014

DOI: 10.3892/mmr.2014.2733

Abstract. Ampelopsin (AMP), a plant flavonoid, has been reported to inhibit cell growth and/or induce apoptosis in various types of tumor. The aim of the present study was to assess the apoptosis-inducing activity of AMP in A549 human lung adenocarcinoma epithelial cells and the associated underlying mechanism. A549 cells were incubated with different concentrations of AMP in culture medium. Cell growth and apoptosis were evaluated by MTT assay and Annexin V/propidium iodide double staining and flow cytometry, respectively. In addition, western blotting and reverse transcription quantitative polymerase chain reaction analysis were used to examine the time-dependent changes in protein expression. Certain changes in apoptotic protein expression were detected following exposure to AMP, including X-linked inhibitor of apoptosis protein release, reduced B-cell lymphoma 2, myeloid cell leukemia 1 and survivin expression levels, increased Bcl-2-associated X protein expression levels and cleaved-poly ADP ribose polymerase expression. The results revealed that AMP was a potent inhibitor of A549 cell proliferation. The c-Myc/S-phase kinase-associated protein 2 (Skp2) and histone deacetylase (HDAC)1/2 pathways were found to exert an important role in AMP-induced A549 cell apoptosis, as increased levels of c-Myc mRNA and reduced levels of c-Myc/Skp2 and HDAC1 and 2 proteins following AMP treatment were observed. The levels of F-box and WD repeat-containing protein 7α (Fbw7α), Fbw7β, Fbw7γ, phosphorylated-(p-) c-Myc (Thr58) and glycogen synthase kinase 3β (GSK3β) proteins involved in c-Myc ubiquitin-dependent degradation were also analyzed. Following exposure to AMP, the expression levels of Fbw7α, Fbw7γ and GSK3β were reduced and p-c-Myc (Thr58) expression levels were increased. The results suggest that AMP exerts an anticancer effect, which is associated with the degradation of c-Myc, Skp2 and HDAC1 and 2. The ability of AMP to induce apoptosis independently of Fbwα and Fbw7γ suggests a possible use in drug-resistant cancer associated with Fbw7 deficiency. Understanding the exact underlying mechanism requires further investigation of the association between c-Myc and Fbw7α/γ reversal, and analysis of whether Thr58 phosphorylation of c-Myc is dependent on GSK3β.

Introduction

Despite multiple clinical trials aimed at improving patient survival rates, lung cancer is the second leading cause of cancer-related mortality worldwide following breast cancer. Among all types of pulmonary cancer, ~85% of cases are diagnosed, commonly at advanced stages, as non-small cell lung cancer (NSCLC) (1). Lung adenocarcinoma is the predominant NSCLC histological subtype, which accounts for 20-30% of primary lung cancer cases among patients <45 years of age, regardless of smoking history (2). The majority of patients with NSCLC exhibit advanced disease, thus are unsuitable for surgery; therefore, chemotherapy remains the cornerstone of treatment.
AMP activity is mediated by the induction of apoptosis and cell differentiation, which is regulated by various genes and proteins (34). In the present study, the effect of AMP upon cell proliferation and apoptosis in the A549 human lung adenocarcinoma epithelial cell line was assessed. In addition, the regulatory effects and underlying functions of the c-Myc/Skp2/Fbw7 and HDAC1/2 pathways involved in the apoptotic effect were investigated.

Materials and methods

Reagents and antibodies. AMP (purity >98%) was supplied by the Institute of Biology at Guizhou Academy of Sciences (Guiyang, China). The following antibodies were used: Fbw7 (cell division control protein 4, H-300) and phosphorylated-(p-) c-Myc (Thr 58) were provided by Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); c-Myc and GSK3β were bought from Proteintech Group, Inc. (Chicago, IL, USA); HDAC1 and 2, Skp2, survivin, B-cell lymphoma 2 (Bcl-2) and β-actin were obtained from Wuhan Boster Biological Technology, Ltd. (Wuhan, China); myeloid cell leukemia 1 (Mcl-1) and X-linked inhibitor of apoptosis protein (XIAP) were provided by Bioss (Beijing, China); and poly ADP ribose polymerase (PARP) was purchased from Sino Biological Inc. (Beijing, China).

Cell culture. A549 human pulmonary adenocarcinoma cells were provided by the Cell Bank of the Animal Experiment Center, North School Region, Sun Yat-Sen University (Guangzhou, China). The A549 cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (Beijing Solarbio Science and Technology Co., Ltd., Beijing, China) at 37°C and 5% CO2.

MTT assay. To measure cell viability, A549 cells harvested with trypsin were seeded onto 96-well plates at a density of 1x104 cells per well. Following overnight incubation, the culture medium was removed and the cells were incubated with different concentrations of AMP in culture medium. After 48 h, MTT was added to each well and incubated at 37°C for an additional 4 h to allow mitochondrial dehydrogenase to convert the MTT into insoluble formazan crystals. The medium was then discarded and 100 μl dimethylsulfoxide (Sigma, St. Louis, MO, USA) was added to each well to dissolve the formazan crystals. The absorption of solubilized formazan was measured at 490 nm using an EL340 microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA).

Nuclear staining. A549 cells were stained using a DAPI staining kit (Nanjing KeyGen Biotech. Co. Ltd., Nanjing, China). Following exposure to graded AMP concentrations for 48 h, the cells were washed and incubated with 1.2 μg/ml DAPI working solution at 37°C for 15 min. The cells were subsequently washed with methanol solution. Buffer A containing 60% glycerol in 10 mM phosphate-buffered saline (PBS; pH 7.6) was added to the suspension. The A549 cells were viewed using an Eclipse Ti Nikon microscope (Nikon Corporation, Tokyo, Japan).

Mitochondrial membrane potential. A JC-1 fluorescent, lipophilic, cationic probe (Beyotime Co., Shanghai, China), was
used to measure the mitochondrial membrane potential ($\Delta\psi_m$) of the A549 cells, according to the manufacturer's instructions. Briefly, the cells exposed to AMP were incubated with 1X JC-1 staining solution for 20 min at 37°C. The cells were then washed twice with JC-1 staining buffer and images were captured with the Eclipse Ti Nikon microscope.

**Apoptosis assay.** A549 cells were labeled with fluorescein isothiocyanate (FITC)-labeled Annexin V and propidium iodide (PI) using an Annexin V-FITC apoptosis detection kit (Nanjing KeyGen Biotech. Co. Ltd.) according to the manufacturer's instructions. Briefly, after 48 h exposure to different AMP concentrations, the cells were washed with cold PBS and then resuspended in 1X binding buffer. Aliquots of $10^5$ cells were mixed with 5 µl Annexin V-FITC and 5 µl PI for 15 min at room temperature in the dark. Fluorescence (530 nm) was detected within 1 h using flow cytometry (FACS Aria; BD Biosciences, Franklin Lakes, NJ, USA).

**Reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis.** RT-qPCR with a SYBR® Green reporter was conducted. The A549 cells exposed to AMP were washed with PBS. Total RNA was purified using RNAiso Plus (Takara, Dalian, China). The resultant RNA was first reverse transcribed to cDNA using a PrimeScript® RT Master Mix kit (Takara). Gene-specific primers were combined with SYBR® Premix Ex Taq™ (Takara) and amplified using an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). All qPCR reactions were conducted independently on five samples. The relative mRNA expression levels were calculated using the $2^{-\Delta\Delta Ct}$ method. The primer sequences are described in Table I.

**Western blot analysis.** Following washes with PBS, the cells were lysed with radioimmunoprecipitation assay buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1% nonyl phenoxyethoxyethanol-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), sodium orthovanadate, EDTA, sodium fluoride and leupeptin (Beyotime Co.). Cytoplasmic proteins were separated using a nuclear and cytoplasmic protein extraction kit (Nanjing KeyGen Biotech. Co. Ltd.). The concentrations of soluble proteins were determined with a bicinchoninic acid protein assay kit (Beyotime Co.). The cell lysates were boiled in loading buffer for 5 min and then separated on a 15% SDS-PAGE gel. The proteins were subsequently transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). The membranes were blocked with Tris-buffered saline-Tween 20 (TBST) containing 5% non-fat milk at room temperature for 1 h, and were incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies (1:10,000; Beyotime Co.) for 1 h at room temperature and visualized with enhanced chemiluminescence detection reagents (Beyotime Co.).

**Statistical analysis.** Data analysis was performed using SPSS version 17.0 software (SPSS, Inc., Chicago, IL, USA). The results are expressed as the mean ± standard error of the
AMP inhibits cell growth and induces cell apoptosis. Cell viability was assessed using an MTT assay together with DAPI staining and flow cytometric analysis, to investigate apoptosis following exposure to different concentrations of AMP. The MTT analysis indicated that AMP inhibited cell growth in a dose-dependent manner (Fig. 1B) and this was confirmed by the results of the flow cytometric analysis using Annexin V-PI (Fig. 1C). As compared with the control group, the early- and late-stage apoptotic rates increased subsequent to exposure to all concentrations of AMP. In the 30 µM AMP group, the total apoptosis rate exceeded 50%. As shown in Fig. 1D, DAPI staining revealed signs of condensed and cleaved nuclei in the cells administered 30 µM AMP, but only clear nuclei with pale blue staining were observed in the control group.

The results also revealed an association between AMP treatment and a dose-dependent decline in the mitochondrial potential (Δψm), with reduced red fluorescence (JC-1 polymer) and increased green fluorescence (JC-1 monomer), as presented in Fig. 2A. This result may have been due to the downregulation of Mcl-1 and Bcl-2 (Fig. 2B). The upregulation of cleaved fragments from PARP (PARP 85) and the downregulation of XIAP and survivin suggest that the apoptotic process continued following mitochondrial damage.

AMP downregulates HDAC2 at the mRNA and protein levels. Significant downregulation of HDAC1 and 2 mRNA following 30 µM AMP treatment, as compared with the control treatment, was detected by qPCR (Fig. 3A). This result is consistent with the finding that HDAC2 protein expression was downregulated in a dose-dependent manner following exposure to different concentrations of AMP for 48 h (Fig. 3B). These changes may result in a subsequent proportional increase in the levels of histone acetylation, therefore enhancing the expression levels of tumor suppressive proteins.

AMP increases c-Myc mRNA expression levels, but downregulates c-Myc and Skp2 expression at the protein level. As shown in Fig. 4A, Skp2 mRNA expression levels were significantly reduced (P<0.05), whereas c-Myc mRNA expression levels were increased up to ~1.6-fold following exposure to AMP (10, 20 and 30 µM) for 48 h, as compared with the control treatment. c-Myc and Skp2 were also downregulated at the protein level (Fig. 4B).

Thr58 phosphorylation of c-Myc is a requirement for c-Myc degradation and is mediated by GSK3β. GSK3β is the only kinase that has been previously demonstrated to phosphorylate c-Myc at Thr58 (35,36). However, in the present study, GSK3β expression following AMP treatment was reduced at the mRNA (Fig. 5A) and protein levels (Fig. 5B), as compared with the control treatment.
with a certain degree of increase in Thr58 phosphorylation of c-Myc (Fig. 5B). These findings indicate that the phosphorylation of c-Myc at Thr58 may occur independently of GSK3β. The process may therefore involve reduced Fbw7α, Fbw7γ and Skp2 expression levels, but the exact pathway for c-Myc degradation requires further investigation.
Discussion

AMP is a naturally occurring flavonoid extracted from Scutellaria baicalensis Radix, which has been reported to exert antineoplastic activity in various types of cancer (28‑34). In the present study, the roles of the c‑Myc/Skp2/Fbw7 and HDAC1/2 pathways, which are associated with tumor progression, on the anticancer effects of AMP in the A549 NSCLC line were investigated. The effects of AMP upon A549 cell proliferation and apoptosis were evaluated using MTT assays and Annexin V‑PI double staining. The results indicated that AMP inhibited cell growth at half maximal
inhibitory concentration <30 µM in a dose-dependent manner. In response to AMP treatment, the early-stage apoptotic rate was increased, since Annexin V-positive cells gradually became Annexin V-negative. Significant apoptosis was observed following 30 µM AMP treatment, as compared with the control treatment, a finding consistent with the morphologic changes observed subsequent to cell nuclear DAPI staining. As shown in Fig. 1D, condensed and cleaved nuclei were detected only in the treatment groups.

To identify the apoptotic effects of AMP treatment at the protein level, the expression levels of apoptosis-related proteins, including Mcl-1, PARP, survivin, Bcl-2 and XIAP were assessed. The results indicated that AMP influenced mitochondrial membrane stability and reduced the mitochondrial membrane potential (ΔΨm; Fig. 2A). This process may be associated with the reduced Bcl-2 and increased Bax expression levels observed (Fig. 2B). Cleaved PARP and reduced XIAP and survivin expression levels may also have partially contributed to the progression of apoptosis.

HDAC1 and 2, Class I HDACs, not only deacetylate histone/non-histone proteins, but also inhibit gene expression and modify tumor suppressive proteins associated with tumor progression (3,4). The results of the present study revealed that the expression levels of HDAC1/2 were reduced at the mRNA and protein levels in the presence of AMP (Fig. 3), indicating that acetylated histone proteins may promote the expression of tumor suppressive proteins and thus inhibit tumor progression.

A previous study demonstrated that c-Myc, as a transcription factor, has the ability to regulate various genes involved in cellular proliferation, differentiation, growth and apoptosis (7). The post-translational regulation of c-Myc is mediated by Skp2 and Fbw7 (12). The c-Myc and Skp2 oncoproteins are inter-related such that c-Myc promotes Skp2 expression and Skp2 targets c-Myc for ubiquitin-dependent degradation. In the present study, AMP downregulated Skp2 expression at the mRNA level and protein levels. In addition, AMP downregulated c-Myc at the protein level, but c-Myc mRNA expression levels were increased (Fig. 4). These findings suggest that the proteasomal degradation pathway may be associated with the reversal of c-Myc. However, since Skp2 expression levels were reduced, subsequent experiments were focused on Fbw7 (which has three isoforms in humans: Fbw7α, β and γ), another proteasome recognition subunit that targets c-Myc.

The involvement of Fbw7 deficiency in drug resistance in human cancer has been recently identified (22,23). In the regulation of c-Myc, Fbw7 is different from Skp2. Thr58 phosphorylation of c-Myc is required for Fbw7αβγ and the phosphorylation of c-Myc at Thr58 may occur independently of GSK3βγ, a finding concurrent with those of previous studies that observed phosphorylation of Thr58 in A549 cells occurring independently of GSK3βγ (37,38).

In conclusion, the results of the present study indicate that AMP influences multiple biochemical pathways, which may explain AMP activity against various types of cancer. In addition, the results may also partially explain why cells deficient in certain genes, for instance Fbw7-deficient cells, are resistant to AMP and suggest a possible use of AMP in drug-resistant cancer associated with Fbw7 deficiency. However, the exact underlying mechanism of AMP action, which pathways are associated with c-Myc and Fbw7αβγ reversal and whether Thr58 phosphorylation of c-Myc is dependent on GSK3βγ requires further investigation.

Acknowledgements

This study was supported by the National Science Foundation of China (no. 81372466); the Ministry of Science and Technology of Guizhou Province, China [nos. (2012) 7006 and NY (2011)3072]; and the Foundation for Young Scientists of Guanzhou Educational Committee (no. 2012C118).

References

1. Juergens R and Brahmer J: Targeting the epithelial growth factor receptor in non-small-cell lung cancer: who, when, where, and how? Curr Oncol Rep 4: 255-264, 2007.
2. Crocetti E and Paci E: Trends in lung adenocarcinoma incidence and survival. Lung Cancer 2: 215-216, 2002.
3. Ruthenberg AJ, Li H, Patel DJ and Allis CD: Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 8: 983-994, 2007.
4. Marks PA and Xu WS: Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107: 600-608, 2009.
5. Slingerland M, Guchelaar HJ and Gelderblom H: Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs 2: 140-149, 2014.
6. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S and van Kuijlenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749, 2003.
7. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsley D and Zeller K: Function of the c-Myc oncogenic transription factor. Exp Cell Res 253: 63-77, 1999.
8. Nesbit CE, Tersak JM and Prochownik EV: MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016, 1999.
9. Flinn EM, Busch CM and Wright AP: Myc boxes, which are conserved in Myc family proteins, are signals for protein degradation via the proteasome. Mol Cell Biol 18: 5961-5969, 1998.
10. Jones TR and Cole MD: Rapid cytoplasmic turnover of c-Myc mRNA: requirement of the 3′ untranslated sequences. Mol Cell 7: 4513-4521, 1987.
11. Kelly K, Cochran H, Stiles CD and Leder P: Cell-specific regulation of the c-Myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 35: 603-610, 1983.
12. Amati B: Myc degradation: Dancing with ubiquitin ligases. Proc Natl Acad Sci USA 101: 8843-8844, 2004.
13. Currano AC, Eytan E, Hershko A and Pagano M: Skp2 is required for ubiquitin-mediated degradation of the CKD inhibitor p27. Nat Cell Biol 1: 193-199, 1999.
14. Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, Hatakeyama S, Nakayama K and Nakayama KE: Degradation of p57 Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci USA 100: 10231-10236, 2003.
15. Tedesco D, Lukas J and Reed SI: The pKb-related protein p30 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF (Skp2), Genes Dev 16: 2946-2957, 2002.
112

16. Hiramatsu Y, Kitagawa K, Suzuki T, Uchida C, Hattori T, Kikuchi H, Oda T, Hatakeyama S, Nakayama KI, Yamamoto T, et al: Degradation of Tob1 mediated by SCFSkp2-dependent ubiquitination. Cancer Res 66: 8477-8483, 2006.

17. Zhao D, Zheng HQ, Zhou Z and Chen C: The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res 70: 4728-4738, 2010.

18. Akhoondi S, Lindström L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grandér D and Sangfelt O: Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res 12: R105, 2010.

19. Inuzuka H, Shaik S, Onoyama I, et al: SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471: 104-109, 2011.

20. Sancho R, Jandke A, Davis H, Diefenbacher ME, Tomlinson I and Behrens A: F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. Gastroenterology 139: 929-941, 2010.

21. O’Neil J and Look AT: Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene 26: 6838-6849, 2007.

22. Wang Z, Fukushima H, Gao D, Inuzuka H, Wan L, Lau AW, Liu P and Wei W: The two faces of FBW7 in cancer drug resistance. Bioessays 11: 851-859, 2011.

23. Wertz IE, Kusam S, Lam C, et al: Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471: 110-114, 2011.

24. Pulverer BJ, Fisher C, Vouwen K, Littlewood T, Evan G and Woodgett JR: Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9: 59-70, 1994.

25. Kim SY, Herbst A, Tworkowski KA, Salghetti SE and Tansey WP: Skp2 regulates Myc protein stability and activity. Mol Cell 11: 1177-1188, 2003.

26. Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M and Reed SI: hCDC4 gene mutations in endometrial cancer. Cancer Res 62: 4535-4539, 2002.

27. Welcker M, Oriam A, Grim JE, Eisenman RN and Clurman BE: A nuclear isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol 14: 1852-1857, 2004.

28. Zhang B, Dong S, Cen X, Wang X, Liu X, Zhang H, Zhao X and Wu Y: Ampelopsin sodium exhibits anti-tumor effects against bladder carcinoma in orthotopic xenograft models. Anticancer Drugs 6: 590-596, 2012.

29. Zheng HQ and Liu DY: Anti-invasive and anti-metastatic effect of ampelopsin on melanoma. Ai Zheng 22: 363-367, 2003 (In Chinese).

30. Zeng S, Liu D, Ye Y, Wang L and Wang W: Anti-tumor effects of ampelopsin on human lung cancer GLC-82 implanted in nude mice. Zhong Yao Cai 27: 842-845, 2004 (In Chinese).

31. Luo GQ, Zeng S and Liu DY: Inhibitory effects of ampelopsin on angiogenesis. Zhong Yao Cai 29: 146-150, 2006 (In Chinese).

32. Ye J, Zheng Y and Liu D: Reversal effect and its mechanism of ampelopsin on multidrug resistance in K562/ADR cells. Zhongguo Zhong Yao Za Zhi 34: 761-765, 2009 (In Chinese).

33. Ni F, Gong Y, Li L, Abdolmaleky HM and Zhou JR: Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice. PLoS One 7: e38802, 2012.

34. Kou X, Shen K, An Y, Qi S, Dai WX and Yin Z: Ampelopsin inhibits H2O2-induced apoptosis by ERK and Akt signaling pathways and up-regulation of heme oxygenase-1. Phytother Res 21: 988-994, 2007.

35. Gregory MA, Qi Y and Hann SR: Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 51: 51606-51612, 2003.

36. Kamemura K, Hayes BK, Comer FL and Hart GW: Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: alternative glycosylation/phosphorylation of THR-58, a known mutational hot spot of c-Myc in lymphomas, is regulated by mitogens. J Biol Chem 21: 19229-19235, 2002.

37. Chen XM, Bai Y, Zhong YJ, Xie XL, Long HW, Yang YY, Wu SG, Jia Q and Wang XH: Wogonin has multiple anti-cancer effects by regulating c-Myc/SKP2/Fbw7a and HDAC1/HDAC2 pathways and inducing apoptosis in human lung adenocarcinoma cell line A549. PLoS One 8: e79201, 2013.

38. Li Q, Kluz T, Sun H and Costa M: Mechanisms of c-Myc degradation by nickel compounds and hypoxia. PLoS One 4: e8531, 2009.